Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732613 | 0.69 | LMNA (0.37) | ALDH1A1CYP3A4HSD17B10TSHRLMNA | |
| SCHEMBL11041326 | 0.66 | ALDH1A1 (0.50) | ALDH1A1CYP3A4HSD17B10TSHRLMNA | |
| Hydrochloric Acid SCHEMBL11850019 | 0.66 | NCEH1 (0.40) | ALDH1A1CYP3A4TSHRLMNAMEN1 | |
| SCHEMBL12799246 | 0.64 | ALDH1A1 (0.67) | ALDH1A1CYP3A4HSD17B10TSHRLMNA | |
| SCHEMBL1402586 | 0.63 | CYP1A2 (0.36) | HSD17B10TSHRMEN1KMT2A | |
| SCHEMBL3341056 | 0.63 | MAPT (0.60) | ALDH1A1CYP3A4LMNAMAPK1MEN1 | |
| SCHEMBL29365600 | 0.63 | MAPT (0.60) | ALDH1A1CYP3A4LMNAMAPK1MEN1 | |
| SCHEMBL27873890 | 0.63 | MAPT (0.34) | — | |
| SCHEMBL11602041 | 0.63 | TDP1 (0.42) | ALDH1A1CYP3A4HSD17B10TSHRLMNA | |
| SCHEMBL31677108 | 0.63 | LTA4H (0.41) | ALDH1A1CYP3A4HSD17B10TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2637649-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | Akron Molecules GmbH (AT) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062925-A2 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES GMBH (AT) | 2012-05-18 | — | — | WO | disclosed |
| US-8067763-B2 | Quantum dot solar cell with conjugated bridge molecule | HONEYWELL INTERNATIONAL INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090159120-A1 | QUANTUM DOT SOLAR CELL WITH CONJUGATED BRIDGE MOLECULE | HONEYWELL INTERNATIONAL INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-0057440-B1 | AMINOPYRIMIDINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND FUNGICIDAL, INSECTICIDAL AND ACARICIDAL COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1985-05-22 | — | — | EP | disclosed |
| US-4435402-A | Aminopyrimidine derivatives, processes for their preparation, and fungicidal, insecticidal and acaricidal compositions containing them | SANKYO COMPANY, LIMITED (JP) | 1984-03-06 | — | — | US | disclosed |
| EP-0057440-A1 | Aminopyrimidine derivatives, processes for their preparation, and fungicidal, insecticidal and acaricidal compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | ALDH1A1 730/4885CYP3A4 2764/4885HSD17B10 1782/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | ALDH1A1 730/4885CYP3A4 2764/4885HSD17B10 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.